The Power of Particle Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Power of Particle Characterization
Pharma's drive for manufacturing efficiency is bolstering particle-characterization technologies.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 42-43

Another way that particle characterization can benefit process development is through simulation, which involves using characterization data to construct mathematical models that predict process performance. These models, if robust, can be used to conduct virtual experiments.

"The big attraction of process simulation is that it allows virtual experimentation, which is cheaper and quicker than the laboratory or pilot scale equivalent," explains Kippax. "The drawback is the effort required to develop a reliable model." Despite this, however, Kippax added that he expects process simulation to become more widely used within in the industry in the coming years because of the potential it has for aiding scale up and troubleshooting.

Future advances

Particle characterization has come a long way from its early days, but there is always room for more progress. "The next major development in particle sizing is likely to be in measuring in three dimensions," says Rideal. "Computer technology will be a driving force where the current impressive computer graphics from the film industry will be incorporated into particle sizing. There is also a move to borrow technology from the medical world, so expect to see X-ray CAT scans and MRI instruments appearing in the particle-metrology laboratory."

Meanwhile, Kippax is hopeful that there will be more advances in laser diffraction. "One goal is to make the performance gains already made more universally accessible. Greater embedded support during method development and throughout the measurement process, for example, would ensure that even inexperienced users could fully exploit the technology."

With such improvements on the horizon, industry's main challenge may not stem from technology, but rather from the skill of the operator using it. "Just because an instrument costs in excess of $100000 does not mean that the results are any better than using a sieve costing £100," says Rideal. "The old adage of 'rubbish in, rubbish out' has never been so relevant."

Reference

1. ICH, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Products: Chemical Substances (May 2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
43%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
14%
Raw material supply problems
14%
Regulatory restrictions
0%
Business decisions to limit production
29%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here